Company intelligence / Profile preview
Cognition Pharmaceuticals
Purchase, New York, USAcogrx.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
Cognition Therapeutics’ lead candidate zervimesine (CT1812) has shown positive results in Phase 2 studies for both dementia with Lewy bodies and Alzheimer’s disease. In DLB, CT1812 demonstrated improvements across behavioral, functional, cognitive, and movement measures. In Alzheimer's disease subgroups, it showed dramatic slowing of cognitive decline. The company plans to advance CT1812 into late-stage registrational trials for both indications in 2025.
- Therapeutic areas
- OphthalmologyNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Collaborations with academic institutions such as the National Institute on Aging and the Alzheimer’s Clinical Trials Consortium; no major pharma partnerships publicly disclosed as of May 2025.
Beyond the preview
Go deeper on Cognition Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cognition Pharmaceuticals.